Vanda Pharmaceuticals, a global biopharmaceutical company, completed the acquisition of Actelion Pharmaceuticals (PONVORY), a Biotech company. Financial terms were not disclosed. "The acquisition of Ponvory is a significant milestone for Vanda, as it expands our commercial portfolio and gives us access to a versatile immune response modifier that can potentially have broad application in treating a number of autoimmune-based disorders," Mihael H. Polymeropoulos M.D., Vanda President CEO and Chairman of the Board.